Vivani Medical Inc
vivani.comWhat Do They Do?
Develops miniature, long-acting subdermal drug implants for people with chronic diseases and companion cats and dogs.
10-K for FY2025, filed Mar 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$6.4MView ↗
- ▼ −11% (Loss)
- vs −$7.1M in Q2 FY2025
-
Jul 7, 2026
Agreed to merge Cortigent into ClearOne
Cortigent would become ClearOne’s wholly owned subsidiary, subject to closing conditions.
Sources
8-K, filed Jul 7, 2026
On July 1, 2026, Vivani Medical, Inc. (“Vivani”) entered into a definitive agreement and plan of merger (the “Merger Agreement”) among its…View ↗
Lead program focus
The older report centered its drug program on a diabetes implant; the latest centers it on a weight-management implant, while retaining a diabetes implant in development.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 26, 2026Vivani resulted from the August 2022 business combination of Second Sight Medical Products, Inc. (Second Sight) and Nano Precision Medical…View ↗
Our emerging portfolio of miniature, ultra long-acting drug implant candidates have the potential to revolutionize the treatment of chronic…View ↗
Who Do They Compete With?
Competes with Lilly, Novo Nordisk, AstraZeneca, Sanofi, Altimmune, Alveus, Amgen, Ascletis Pharma, Biomea, D&D Pharmatech, Fractyl Health, Gan & Lee, Innovent, Merck, Mindrank, Pfizer, Roche, Viking Therapuetics, Zealand Pharma, and Teva
10-K for FY2025, filed Mar 26, 2026The competition for Vivani will be dependent upon the individual product candidate in development. For Vivani’s lead programs, NPM-139…View ↗
Loading...
